The improved function of the intestinal barrier prevents the entry of endotoxins into the liver, thus inhibiting the expression of the TLR4/NF-κB pathway, mitigating inflammation and the resulting hepatic steatosis. This evidence concerns the gene TLR4 and fatty liver disease.